Send the link below via email or IMCopy
Present to your audienceStart remote presentation
- Invited audience members will follow you as you navigate and present
- People invited to a presentation do not need a Prezi account
- This link expires 10 minutes after you close the presentation
- A maximum of 30 users can follow your presentation
- Learn more about this feature in our knowledge base article
Do you really want to delete this prezi?
Neither you, nor the coeditors you shared it with will be able to recover it again.
Make your likes visible on Facebook?
You can change this under Settings & Account at any time.
Morning Report 7/15/13
Transcript of Morning Report 7/15/13
HERPES SIMPLEX VIRUS (HSV) ENCEPHALITIS
Review the history and epidemiology of HSE
Learn about the pathogenesis of HSE
Describe the clinical presentation of HSE
Consider the differential diagnosis of HSE
Understand how to diagnose HSE
Know the appropriate treatment for HSE
Zarafonetis and coworkers (1944) –
HSV first isolated in adult brain
-Intranuclear inclusion bodies
-Temporal lobe localization
-Perivascular cuffs of lymphocytes
-Numerous small hemorrhages
Nahmias and Dowdle (mid-1960s) –
viral typing: HSV-1 & HSV-2
“Above the belt” and “below the belt”
A Devastating Disease
HSV infection of the brain is the most common cause of sporadic fatal encephalitis in the USA.
In patients who do not receive treatment:
Mortality rate > 70%
Only ~15-38% of survivors return to normal function after treatment.
As of 2005, incidence was estimated between 1 in 250,000 and 1 in 500,000.
HSV encephalitis accounts for 10-20% of 20,000 annual viral encephalitis cases
75% of cases occur in adults, 1/2 of which are in patients older than 50 years
Both sexes equally affected
Acute neurologic/psychiatric symptoms (<1 week duration):
AMS and altered level of consciousness
Cranial nerve deficits
PATIENTS NEARLY ALWAYS HAVE FEVER IN ADDITION TO ONE OF THE ABOVE SYMPTOMS!
CSF cell counts not specific for HSV.
Pleocytosis & proteinosis (average protein 100mg/dL)
Absence of bacterial & fungal pathogens in the CSF
***PCR DETECTION of HSV DNA
diagnostic method of choice (94% sensitivity & 98% specificity)
CSF is indicated - assuming no signs of increased ICP
ABCs - Remember: Less than 8 [GCS] ... INTUBATE
DO NOT WAIT to start treatment...MUST BE STARTED BEFORE onset of HEMORRHAGIC NECROSIS and DETERIORATION OF CONSCIOUSNESS.
TREATMENT OF CHOICE:
ACYCLOVIR: 10 mg/kg/dose q8 hours for 14 days
(Per IDSA Guidelines 2008)
Viral Intranuclear Inclusion Cells in temporal lobe of a patient with HSE
Herpes Simplex Figure 48.
HSV Viral Particles in an Intranuclear inclusion cell
This is seen in 50% of patients with HSE
Most often visible in the first week of infection
Replicating HSV causes degeneration of cellular nuclei, loss of intact plasma membranes, and formation of multinucleated giant cells.
Results in acute inflammation (influx of mononuclear cells), congestion, and/or hemorrhage.
Most notably in the temporal lobes.
Adjacent limbic & frontal areas may also be involved.
After about 2 weeks, changes proceed to frank necrosis and liquefaction of involved brain tissue.
Due to HSV type 1 (HSV-1) in nearly all cases
Occurs through one of three routes:
-Immediate invasion in the CNS via trigeminal nerve following episode of primary HSV-1
-CNS invasion after episode of recurrent HSV-1, representing viral reactivation
-CNS infection without primary or recurrent infection, representing reactivation of latent HSV.
Reveals temporal lobe abnormalities in >90% of PCR-proven cases.
Characteristic MRI changes occur early in the course of HSV encephalitis and include high signal intensity lesions on T2-weighted and FLAIR images involving the medial and inferior temporal lobes with extension into the insula.
Non-specific, focal findings in >80% - slowing in temporal and frontal regions
"Love is for now, herpes is forever."
Immunocompromised Patients with HSE
Study by Tan et al, 2012 published in American Academy of Neurology - retrospective review of patients at JHU from 1997-2010
Immunocompromised states - chronic HIV infection, transplant recipients, patients on immunosuppressive therapies, patients with active malignancy, diabetics, and patients with renal insufficiency
May predispose to HSE with atypical features
Fewer patients presented with prodromal symptoms and focal neurologic deficits
Immunocompromised individuals have worse outcomes and mortality
Mortality rate almost 6 times as high
Decreased performance by 23 points on the Karnofsky Performance Status Scale (p=0.018)
Two out of 14 immunocompromised patients had recurrent HSE.
1. Baringer (2008) Herpes simplex infections of the nervous system In Neurologic Clinics, 26: 657-674.
2. Riancho, Delgado-Alvarado, Sedano, Polo, and Berciano. (2013) Herpes simplex encephalitis: clinical presentation, neurological sequelae and new prognostic factors. Ten years of experience. In Neurological Sciences (Epub ahead of print)
3. Tan, McArthur, Venkatesan, and Nath. (2012) Atypical manifestations and poor outcome of herpes simplex encephalitis in the immunocompromised. In American Academy of Neurology, 79: 2125-2132.